Less than two months after scoring what analysts deemed a "best-case" FDA approval for its cardiomyopathy drug Attruby, ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The biopharma industry’s deal-a-palooza, better known as the J.P. Morgan Healthcare Conference, has kicked off in San ...

What connects a broken windshield, a raccoon infestation and Peyronie’s disease? | What connects a broken windshield, a ...

At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...

Y-mAbs Therapeutics is parting ways with its chief commercial officer and putting a new hire in charge of the cancer drug ...

BioDuro, which was formed in 2005 in San Diego and China originally as a CRO, merged with contract manufacturer Formex in ...

Nancy McGee, VP & GM, U.S. Patient Support Services, IQVIAJennifer Millard, VP, U.S. Integrated Patient Support Services, ...

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...